602 related articles for article (PubMed ID: 28929484)
1. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
[TBL] [Abstract][Full Text] [Related]
2. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
Apolone G; Joppi R; Bertele' V; Garattini S
Br J Cancer; 2005 Sep; 93(5):504-9. PubMed ID: 16136026
[TBL] [Abstract][Full Text] [Related]
3. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
4. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
5. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
[TBL] [Abstract][Full Text] [Related]
6. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.
Omae K; Kataoka Y; Tsujimoto Y; Tsutsumi Y; Yamamoto Y; Fukuhara S; Furukawa TA
BMC Cancer; 2019 Oct; 19(1):998. PubMed ID: 31651263
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
Nagai S; Ozawa K
Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
[TBL] [Abstract][Full Text] [Related]
8. Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.
Nagai S; Ozawa K
Invest New Drugs; 2018 Jun; 36(3):487-495. PubMed ID: 29453626
[TBL] [Abstract][Full Text] [Related]
9. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rosian K; Wild C; Simon J
Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
[TBL] [Abstract][Full Text] [Related]
10. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
[TBL] [Abstract][Full Text] [Related]
11. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.
Zeitoun JD; Ross JS; Atal I; Vivot A; Downing NS; Baron G; Ravaud P
BMJ Open; 2017 Dec; 7(12):e018587. PubMed ID: 29273664
[TBL] [Abstract][Full Text] [Related]
12. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
13. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
14. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
17. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
18. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
Hwang TJ; Tomasi PA; Bourgeois FT
PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
[TBL] [Abstract][Full Text] [Related]
19. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
20. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
